Thermo Fisher and Juno sign seven-year CAR-T tech deal

By Flora Southey contact

- Last updated on GMT


Related tags: Thermo fisher, Thermo fisher scientific, Thermo electron

Juno Therapeutics will use Thermo Fisher Scientific’s Cell Therapy Systems (CTS) technology to develop CAR T therapies for cancer treatments.

The agreement will see Thermo Fisher supply Juno with CTS Dynabeads CD3/CD28 for seven years in a nonexclusive licensing deal.

Thermo Fisher said the magnetic beads – which it makes at its manufacturing facility in Vilnius, Lithuania – activate and expand T cells specially designed to identify and combat cancer cells in patients. 

“Thermo Fisher’s Dynabeads T cell expansion bead platform is already proven in commercial manufacturing, and is known for greater stability and scalability, which are critical requirements for CAR T manufacturers,” ​Thermo Fisher COO Mark Stevenson told us.

According to Stevenson, the firms have worked together since Juno was founded in 2013.

“Today’s announcement formalises the relationship to allow maximum collaboration to bring product to patients,” ​he said.

Financial details of the deal were not disclosed.

Thermo Fisher also supplies​ its CTS Dynabeads technology for CAR-T immunotherapies to Swiss firm Novartis.

The US Food and Drug Administration (FDA) approved​ Novartis’ CAR-T immunotherapy Kymriah (tisagenlecleucel) in August last year, making it the first commercially available CAR-T treatment in the US.

Related news

Show more

Related products

show more

High quality excipients and formulation support

High quality excipients and formulation support

Roquette Pharma Solutions | 09-Nov-2021 | Product Brochure

As the world grapples with the effects of ongoing health crises, the market is expanding quickly as developers shift their focus to proactive therapeutics....

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Related suppliers

Follow us


View more